Boston, MA 05/29/2013 (wallstreetpr) – In Tuesday’s trading session, shares of Vermillion, Inc (NASDAQ:VRML) rose by 9.42%. The opening price $3.09 touched an intraday high of $3.40 before dipping to $3.09 per share. More than 0.481M shares were traded in Tuesday’s trading session which was higher than the average volume of 0.327M that was measured over a period of 30 days
Incorporated on 23 May 2000, Vermillion, Inc (NASDAQ:VRML) is involved in discovering, developing and commercializing diagnostic tests. These tests help physicians is diagnosing, treating and improving outcomes for patients. Vermillion, Inc (NASDAQ:VRML)’s tests are meant to help doctors make decisions regarding patient treatment. These decisions may include decisions about referring patients to specialists, to have additional testing done, or even to help in selection the right therapy. It combines various biomarkers into one reportable index score. Vermillion, Inc (NASDAQ:VRML) focuses the development of these diagnostic tests in fields such as cardiology, oncology and women’s health. The initial focus is on ovarian cancer. OVA1, which is VRML’s product, addresses unmet clinical needs, such as pre-surgical identification of malignant ovarian tumor in high-risk female patients. Several studies have been documented which indicate that women have benefited from being referred to gynecologic oncologists for initial surgery.
Apart from OVA1, Vermillion, Inc (NASDAQ:VRML) has development programs in various other clinical factors surrounding ovarian cancer. Peripheral arterial disease is another area that is covered. In this latter field, VRML has identified few candidate biomarkers that might help in identifying individuals who are at high risk for a reduced ankle-brachial index score. This is indicative of the possible presence of peripheral arterial disease.
